- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | Polyrizon erhält Zulassung für klinische Studie zu Allergen-Nasenspray | - | Investing.com Deutsch | ||
| Mo | Polyrizon Ltd.: Polyrizon Makes Strong Progress: Receives Central IRB Approval for its Allergy Blocker Clinical Trial | 161 | GlobeNewswire (Europe) | Raanana, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 17.06. | Polyrizon receives U.S. patent publication notice for nasal drug delivery platform | 4 | Seeking Alpha | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 17.06. | Polyrizon Ltd.: Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform | 313 | GlobeNewswire (Europe) | Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 15.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | Klinische Studie zu Allergieblocker treibt Polyrizon Aktie an | 2 | Investing.com Deutsch | ||
| 15.06. | Polyrizon initiates nasal residence time study for allergy blocker | 2 | Investing.com | ||
| 15.06. | Polyrizon Ltd.: Polyrizon Advances NASARIX Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway | 1 | GlobeNewswire (USA) | ||
| 10.06. | Polyrizon Marches on European Patent | - | Baystreet.ca | ||
| 10.06. | Polyrizon receives European patent application publication | 1 | Investing.com | ||
| 10.06. | Polyrizon Ltd.: Polyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology | 322 | GlobeNewswire (Europe) | Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
| 08.06. | Polyrizon signs two more U.S. sites for allergy trial | 1 | Investing.com | ||
| 08.06. | Polyrizon Ltd.: Polyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX Trial | 1 | GlobeNewswire (USA) | ||
| 05.06. | Polyrizon verlängert Exklusivitätsfrist für Übernahmegespräche mit Arrow Aviation | 1 | Investing.com Deutsch | ||
| 05.06. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 13.05. | Polyrizon signs first clinical trial agreement for allergy drug | 1 | Investing.com | ||
| 13.05. | Polyrizon Ltd.: Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX Allergy Blocker Clinical Trial | 1 | GlobeNewswire (USA) | ||
| 13.05. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 3 4 5 Weiter >>
86 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,455 | +1,64 % | QIAGEN NV - Stabilität als strategische Zone | ||
| NOVAVAX | 8,210 | -0,36 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 10,710 | -0,74 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| BIOXXMED | 0,770 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| OCUGEN | 1,306 | -2,83 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,962 | -0,62 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,820 | 0,00 % | COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment | TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") announced the next steps in connection with changes to the Company's... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,335 | -3,18 % | NurExone stärkt die Schutzmauer um ExoPTEN - globale Patente als Werttreiber | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,420 | -3,14 % | Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why | ||
| REDHILL BIOPHARMA | 0,860 | +1,80 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| XOMA ROYALTY | 37,000 | 0,00 % | XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date | EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) ("XOMA" or the "Company") today announced that its Board of Directors has authorized the following cash... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 1,025 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series | King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,449 | +4,18 % | Onco-Innovations beauftragt Nanosoft Polymers, um die Entwicklung von Polymeren und Wirkstoffverabreichungssystemen für ONC010 zu voranzutreiben | Vancouver, Kanada - 23. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben, dass... ► Artikel lesen | |
| NOVOCURE | 13,015 | -2,22 % | Novocure's Optune Pax Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer | The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant... ► Artikel lesen |
POLYRIZON LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,100 (-0,79 %) liegt der Kurs bei 12,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.